Understanding COVID-19 in kidney transplant recipients in Brazil

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize the demographics, clinical conditions, and outcomes of COVID-19 in kidney transplant recipients across multiple centers in Brazil. It focuses on patients who have tested positive for SARS-CoV-2 and examines factors such as the need for mechanical ventilation, dialysis, and ICU admission. The study will also assess outcomes like death and graft loss within three months after infection. By gathering this data, the research seeks to provide insights into the atypical presentation and progression of COVID-19 in immunosuppressed individuals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Kidney transplant recipients, which may be multi-organ recipients, transplanted in any follow-up period;
2. Positive diagnostic test for COVID-19 (detection of viral load, test for detection of antigens or tests for detection of antibodies);
3. Outpatient or hospital management;
4. Adults and children.

Exclusion Criteria:

\-

Where it's running

• Hospital do Rim
  São Paulo, Aão Paulo, Brazil Recruiting

Study contacts

• Study coordinator: Helio Tedesco
• Email: heliotedesco@medfarm.com.br
• Phone: +55 11 5087-8113

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cardiovascular health five years after MIS-C in children

  This study tests whether kids who had MIS-C still show cardiovascular differences five years later compared with healthy peers.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07659847

• Remdesivir to prevent severe COVID-19 in kidney transplant patients

  This study will try giving remdesivir around the time of transplant to see if it prevents severe COVID-19 in adults receiving a kidney transplant who are currently SARS‑CoV‑2 positive with no or mild symptoms.

  Recruiting Phase 2 Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Badalona, Barcelona · NCT07197164

• 2-HOBA to reduce persistent immune activation in Long COVID with POTS

  This trial will test whether 2‑HOBA, a compound that scavenges harmful IsoLG-adducts, can reduce immune activation in adults with Long COVID who have POTS.

  Recruiting Phase 2 Vanderbilt University Medical Center · Nashville, Tennessee · NCT07189936

• TFH-targeting COVID-19 booster vaccines with and without the 's3' component

  This trial will test two experimental COVID-19 booster vaccines — one with an added 's3' component and one without — in healthy adults 40–64 to see if 's3' makes immune responses bigger, broader, and longer-lasting and to check safety.

  Recruiting at 2 sites Phase 1/2 University of California, Los Angeles · Los Angeles, California and 1 other locations · NCT06810934

• Evaluating Baricitinib for Long COVID Symptoms

  This study is testing if the medication baricitinib can help adults with Long COVID feel better physically and mentally compared to a placebo.

  Recruiting at 17 sites Phase 3 Vanderbilt University Medical Center · Tucson, Arizona and 16 other locations · NCT06631287

• Using letermovir to prevent CMV infection in kidney and pancreas transplant patients

  This study is testing if letermovir can help prevent CMV infections in adult kidney and pancreas transplant patients who are at high risk, while reducing their need for another medication called ganciclovir.

  Recruiting Phase 3 University of Wisconsin, Madison · Madison, Wisconsin · NCT06407232

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.